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Abstract The costimulatory receptor CD28 and IL-4Ra-
containing cytokine receptors play key roles in controlling
the size and quality of pathogen-speciﬁc immune respon-
ses. Thus, CD28-mediated costimulation is needed for
effective primary T-cell expansion and for the generation
and activation of regulatory T-cells (Treg cells), which
protect from immunopathology. Similarly, IL-4Ra signals
are required for alternative activation of macrophages,
which counteract inﬂammation by type 1 responses. Fur-
thermore, immune modulation by CD28 and IL-4 is
interconnected through the promotion of IL-4 producing
T-helper 2 cells by CD28 signals. Using conditionally
IL-4Ra and CD28 deleting mice, as well as monoclonal
antibodies, which block or stimulate CD28, or mAb that
deplete Treg cells, we have studied the roles of CD28 and
IL-4Ra in experimental mouse models of virus (inﬂuenza),
intracellular bacteria (L. monocytogenes, M. tuberculosis),
and parasite infections (T. congolense, L. major). We
observed that in some, but not all settings, Treg cells and
type 2 immune deviation, including activation of alterna-
tive macrophages can be manipulated to protect the host
either from infection or from immunopathology with an
overall beneﬁcial outcome. Furthermore, we provide direct
evidence that secondary CD8 T-cell responses to i.c. bacteria
are dependent on CD28-mediated costimulation.
Keywords CD28  Costimulation  IL-4  IL-4R 
Alternatively activated macrophages  Mouse models 
Conditional knockout  Monoclonal antibodies 
Regulatory T-cells  Inﬂuenza  L. monocytogenes 
M. tuberculosis  T. congolense  L. major
This article is published as part of a Special Issue on Pathogen
Variation and Host Response in Infectious Disease.
T. Hu ¨nig (&)  F. Lu ¨hder  K. Elﬂein  T. Gogishvili 
M. Fro ¨hlich
Institute for Virology and Immunobiology,
University of Wu ¨rzburg, Versbacher Str. 7,
97078 Wu ¨rzburg, Germany
e-mail: huenig@vim.uni-wuerzburg.de
F. Lu ¨hder
e-mail: fred.luehder@med.uni-goettingen.de
K. Elﬂein
e-mail: kleinefee@email.de
T. Gogishvili
e-mail: t_gogishvili@vim.uni-wuerzburg.de
M. Fro ¨hlich
e-mail: Monika.Froehlich@stud-mail.uni-wuerzburg.de
F. Lu ¨hder
Institute for Multiple Sclerosis Research,
University of Go ¨ttingen and Gemeinnu ¨tzige Hertie-Stiftung,
Waldweg 33, 37073 Go ¨ttingen, Germany
R. Guler  A. Cutler  F. Brombacher
International Centre for Genetic Engineering and Biotechnology
(ICGEB) and Institute of Infectious Disease and Molecular
Medicine (IIDMM), Division of Immunology,
University of Cape Town, 7925 Cape Town, South Africa
e-mail: Reto.Guler@uct.ac.za
F. Brombacher
e-mail: fbrombac@mweb.co.za
A. Cutler
Histocompatibility and Immunogenetics Research Group,
NHS Blood and Transplant, London NW9 5BG, UK
123
Med Microbiol Immunol (2010) 199:239–246
DOI 10.1007/s00430-010-0156-zIntroduction
An immune response to an infection can be called suc-
cessful (a) if the invading pathogen is eliminated or at least
effectively controlled and (b) if this aim is reached without
excessive damage to the host. To insure success, tight
qualitative and quantitative regulation of the immune
response is needed. Thus, different types of pathogens call
for different arms from the warehouse of immune effector
mechanisms. Overshooting responses are avoided by an
equally diverse set of counter-regulating measures. The
choice of the appropriate weapon against an invader
becomes manifested in terms of T-helper subset differen-
tiation. However, this is guided by signals from innate
immune cells generated in response to pathogen class
recognition via PAMPs. Limitation of immune responses is
achieved by antigen and growth factor deprivation (with
the exception of chronic infections), the induction and
activity of negative regulators such as CTLA-4, BTLA, or
PD1 in cis, i.e., on the effector cells themselves, and by
‘‘regulatory’’ T-cells (Treg cells) and ‘‘alternatively acti-
vated’’ macrophages (aamMphs) acting as dominant sup-
pressor cells in trans.
Among the cytokines and costimulatory receptors reg-
ulating the balance between a highly effective immune
response with the smallest possible collateral damage, the
Th2 signature cytokine IL-4 and the costimulator CD28
occupy key positions. This is illustrated by the phenotype
of the corresponding knockout mice that show imbalanced
responses when challenged with pathogens.
IL-4 and IL-13 share a common signaling pathway
through the IL-4 receptor a (IL-4Ra) chain. A functional
IL-4R (type 1) requires assembly of IL-4Ra with a cc
chain, while interaction of IL-4Ra with an IL-13Ra1 sub-
unit leads to formation of a functional IL-13 receptor (type
2) [1]. Therefore, by blocking or deleting IL-4Ra, IL-4 and
IL-13 functions are abrogated. While this is the case for
most responses, more recent studies showed some evidence
that IL-13 bound to IL-13Ra2, which was believed to be a
decoy receptor for IL-13 [2] but may also induce signaling
in certain cells under particular conditions [3].
More than a decade ago, constitutive IL-4Ra deﬁcient
mice were generated by using homologous recombination
in embryonic stem cells [4]. Subsequent studies in this
mutant mouse strain, including comparative studies in IL-4
and IL-13 deﬁcient mice, uncovered important biological
roles for IL-4Ra-responses mediated by IL-4 and IL-13. It
turned out that Il-13, believed to be the small brother of
IL-13,hadoverlappingroles,butalsostrikinglydistinctroles,
particularly in activating certain effector functions [5].
In the case of CD28, originally deﬁned as the main
costimulator of primary T-cell responses, genetic deﬁ-
ciency leads to an impairment of antibody responses (but
less of cell-mediated immunity) [6], along with defective
Th2 polarization and a marked reduction in regulatory
T-cells [7], indicating that CD28-mediated costimulation is
of particular importance for Treg and type 2 responses
(including alternative macrophage activation via IL-4),
while being less critical for cell-mediated immunity.
Importantly, such observations made in constitutively
gene-deleted mice are unlikely to reveal the full impor-
tance of the relevant molecules in immune regulation due
to the enormous plasticity of the immune system during
and also after its maturation, which allows adaptational and
back-up mechanisms to overcome at least some of the
deleterious effects of genetic defects. Furthermore, the role
these molecules play when expressed by particular cell
types remains unaddressed. Accordingly, interference with
the expression or function of immune regulators at the time
of infection or in a cell type speciﬁc manner has become
the most important tool in the analysis of their protective
and pathological effects in vivo. Experimentally, this is
achieved by ‘‘conditional’’ gene targeting using the Cre/
loxP system. This strategy has been successfully employed
for the IL-4Ra. Speciﬁcally, mice which are selectively
IL-4Ra deﬁcient in macrophages and neutrophils [8],
smooth muscle cells [9], the CD4? T-cell subpopulation
[10] or T-cells [11] as well as B cells and dendritic cells
(unpublished) have been used to probe IL-4Ra function in
these cell types after various immune and non-immune
challenges. More recently, conditionally deleting CD28
knockout mice have also been generated (F.L. and T.H.,
unpublished). In addition to this genetic approach, both
blocking and stimulatory CD28-speciﬁc mAb were devel-
oped [12] which allow acute interference with [13]o r
activation of [14] this receptor during an immune response.
Interference with CD28-mediated costimulation
Conditional CD28 knockout mice were generated by
ﬂanking exons 2 and 3 with LoxP sequences, allowing
effective deletion when crossed to the appropriate Cre
transgenic lines (F.L., unpublished). Importantly, these
mice also delete CD28 in an inducible fashion when a
tamoxifen-regulated transgene is introduced. For the ﬁrst
time, this will allow to study the importance of CD28 in the
recall of memory responses, an area of controversy for
many years [15, 16]. Previous attempts to address this issue
by monoclonal antibody blockade were hampered by the
facts that a) no truly ligand-binding site-speciﬁc mAb to
CD28 was available (but see below), and b) that blocking
of CD80 and CD86, the ligands of CD28, confounded
results by also depriving the negative regulator CTLA-4
(CD152) of these same ligands [17]. Similarly, transfer of
memory T-cells into CD80/CD86 deﬁcient hosts [17] does
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123not allow to attribute the observed effects upon restimu-
lation with the pathogen to a lack of CD28-mediated
costimulation because again, CTLA-4 engagement is also
affected.
First results using Listeria monocytogenes infection
indicate that indeed, targeted deletion of CD28 between the
establishment and recall of memory strongly impairs the
secondary CD8 T-cell response to a model antigen
expressed by the Listeria (M.F., T.G., F.L., T.H., unpub-
lished). This is most likely due to a direct effect on the CD8
T-cells because the elimination of CD4 T-cells (including
Treg cells) was shown to result in an increase rather than a
decrease of the secondary CD8 T-cell response in the same
system [18]. An example of the results thus obtained is
given in Fig. 1a.
In order to study the importance of CD28-mediated
costimulation for secondary T-cell responses, we have not
only established inducible gene targeting but also the ﬁrst
mAb to mouse CD28 which fully blocks binding of natural
ligands [12, 13]. This mAb was generated in mice, per-
mitting prolonged treatment without the induction of neu-
tralizing antibodies. Indeed, application of this mAb, called
E18, in GvHD [13] and in a mouse asthma model (T.G. and
T.H, unpublished) has shown high therapeutic efﬁcacy.
When again tested for interference with CD8 T-cell
memory recall in the Listeria model, a strong reduction of
clonal expansion was observed, corroborating our results
obtained with conditional gene targeting (Fig. 1b).
Immune deviation and Treg activation with stimulatory
CD28-speciﬁc antibodies
In the course of generating the ﬁrst rat CD28-speciﬁc mAb,
we discovered a novel class of such mAb which is able to
trigger T-cell activation without the engagement of the
TCR [19]. In contrast to conventional CD28-speciﬁc mAb,
which bind monovalently close to or at the natural ligand-
binding site, such ‘‘CD28 superagonists’’ (CD28SA) bind
laterally, allowing lattice formation by crosslinking of
individual CD28 homodimers [20, 21]. This correlation
between function and topology of binding was observed in
rats, mice, and humans [12, 20]. In rodents, CD28 super-
agonists induce immune deviation to Th2 [22] as well as
expansion and functional activation of ‘‘natural’’ Treg cells
[23–25]. Accordingly, such mAb have high therapeutic
efﬁcacy in a wide range of rodent models of autoimmunity,
inﬂammation, and allograft rejection [25–31]. Moreover,
CD28SA application expands the T-cell compartment in
lymphopenic hosts, promoting recovery from immunoin-
competence [32]. While the disastrous outcome of a ﬁrst-
in-man-study of a human CD28SA [33] has interrupted
further development of CD28SA-based therapeuticals,
these antibodies continue to be useful tools for the
manipulation of the rodent immune system in attempts to
study the contribution of immune deviation and/or Treg
activation in the control of immunopathology.
With regard to the effects of CD28SA on the course of
infections and microbe-induced inﬂammatory responses in
rodent models, the following results have been obtained:
1. Adjuvantarthritis.Inthismodel,aTh1responseofLEW
rats to heat-killed mycobacteria in adjuvant results in
swelling and inﬂammation of joints along with exten-
sivecartilagedestruction.Applicationofthemouseanti-
rat CD28SA JJ316 is highly efﬁcacious in preventing
and even reversing pathology in both preventive and
therapeutic settings ([34] and unpublished).
2. Mouse Inﬂuenza. Intranasal infection of mice with
the Inﬂuenza A HKx31 (H3N2) leads to transient
weight loss, lung pathology, and high levels of pro-
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Fig. 1 Secondary CD8 T-cell response to Listeria is CD28 depen-
dent. Mice were infected with 5000 CFU Lm-OVA, challenged with
10
5 CFU on day 30, and analyzed for OVA-speciﬁc splenic CD8 cells
by staining with K
b/SIINFEKL tetramers 5 days later. In A, CD28
-/ﬂ
C57BL/6 mice were used, and CD28 deletion was induced by
tamoxifen in oil feeding (‘‘TM’’, 2.5 mg/dose) on days 24–27; oil
only served as control. In B, wt C57BL/6 mice were treated with the
blocking CD28-speciﬁc mAb E18 (100 lg/dose) on days 29, 31, and
33. ***P\0.0001
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123inﬂammatory cytokines in the bronchoalveolar lavage
and plasma. Application of the mouse anti-mouse
CD28SA D665 alleviates weight loss and inﬂamma-
tion without compromising the control of the infection,
an effect mapped to Treg activation by its recapitula-
tion when Treg cells from D665-stimulated cells were
transferred (Fig. 2 and unpublished observations).
Shown are the marked increases in Treg cells in the
bonchoalveolar lavage of ﬂu-infected mice under
CD28SA treatment (Fig. 2a), as well as the decrease
in TNF and the increase in IL-10 in the lung after
D665 stimulation or transfer of Treg cells from D665-
stimulated mice (Fig. 2b). In this setting, therefore, it
is possible to contain immune-mediated damage to the
host by mAb-mediated Treg stimulation.
3. Mouse trypanosomiasis. A similar protective effect
against immunopathology via experimental Treg stim-
ulation was observed in mice infected with Trypano-
soma congolense [35]. In this model of African
trypanosomiasis, CD28SA treatment down-regulated
IFNc and TNF production by T-cells along with the
production of reactive oxygen species by classically
activated macrophages. Interestingly, it also triggered
the development of alternatively activated macro-
phages, in line with a CD28SA-induced Th2 shift
and IL-4 production [22]. With regard to pathology,
CD28SA treatment delayed the onset of liver injury,
diminished the anemia burden, and prolonged the
survival of infected animals.
4. Mouse TB. Here, the TH1 response to inhaled
Mycobacterium tuberculosis is required for pathogen
containment. CD28SA treatment during M. tuberculo-
sis infection increased the percentage of Treg cells
systemically as well as in the lung (Fig. 3b), where it
also increased IL-10 production (Fig. 3b) but had no
effect on bacterial burden in the lung, liver, or spleen
(Fig 3c).
5. Mouse leishmaniasis. As is the case in mouse TB for
the intracellular bacterium M. tuberculosis, the control
of the parasite burden in Leishmania major depends on
a pro-inﬂammatory Th1 response [36]. We either
depleted Treg cells with CD25-speciﬁc mAb, or
polyclonally stimulated the Treg and Th2 compartment
with the CD28SA D665 from week 4 to week 10 post-
infection. In both C57BL/6 ‘‘healer’’ and BALB/c
‘‘progressor’’ strains, increased DTH (Th1) responses
to Leishmania antigens were observed when Treg cells
were depleted after infection, whereas CD28SA treat-
ment decreased the reaction, in line with the role of
Treg cells and a type 2 response in this system
(Fig. 4a). Furthermore, swelling of the infected foot-
pad (Fig. 4b), parasite load in the infected footpad
(Fig. 4c), and antigen-speciﬁc IFN-c production in
C57BL/6 mice (Fig. 4d) were negatively inﬂuenced by
CD28SA treatment and improved by Treg depletion.
Progression of L. major infection, DTH responses, and
parasite loads in IL-4Ra-/- mice were largely unaf-
fected by CD28SA treatment versus controls (not
shown), suggesting that enhancement of type 2 (as
compared to Treg) responses may be responsible for
the CD28SA effect in C57BL/6 and BALB/c mice
(Table 1).
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Fig. 2 CD28SA-activated Treg
cells suppress inﬂammatory
cytokine response in the lung of
inﬂuenza-infected mice.
C57BL/6 mice were i.n.
infected with 2 9 10
5 pfu
Inﬂuenza A HK 9 31. In A,
mice were treated with 100 lg
of the CD28SA D665 or isotype
control antibody on the day of
infection, and BAL was
obtained after sacriﬁce on day 6.
Treg cells among CD4 cells
were quantiﬁed by i.c. staining
against Foxp3. (b)A si n( a), but
with an additional group of
infected mice receiving 10
6
puriﬁed Treg cells from D665-
treated uninfected mice i.v. on
day one of infection. BAL was
analyzed by ELISA for TNF
and IL-10 on day 6
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123Interference with IL-4Ra-mediated cell signaling
The role of alternatively activated macrophages in
infectious and inﬂammatory disease
Macrophage activation can be divided into a classical and
an alternative pathway. IFN-c-induced, classically acti-
vated macrophages (caMphs) are indispensable for pro-
tective effector responses against intracellular pathogens,
particularly due to their highly effective killing effector
function. However, excessive inﬂammatory immune
responses mediated by caMphs can also be detrimental to
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Fig. 4 CD28SA dampens while anti-CD25 treatment enhances type-
1 immunity during L. major infection. C57BL/6 (n = 4/group) or
BALB/c (n = 3 or 4/group) were treated i.p. with CD28 superagonist
(D665, 50 lg/mouse), isotype control (MOCP31, 50 lg/mouse) or
anti-CD25 (PC61, 100 lg/mouse) from week 4 to week 10 post-
infection with 2 9 10
6 L.major LV39 (MRHO/SV/59/P) metacyclic
promastigotes into the hind footpad. a DTH responses were assessed
every 24 h for 4 d following subcutaneous injection of 10 lgo f
soluble leishmania antigen (SLA). (B ? C) Disease progression was
measured by lesion development and parasite load. b Footpad
swelling was measured at weekly intervals post-infection and
c footpad parasite load determined by limiting dilution of single-
cell suspensions from homogenized footpads at week 10 post-infection.
d IFN-c production was measured in popliteal lymphnode cell cultures
pulsed with SLA (50 lg/ml) from week 10 L. major–infected mice.
Statistical analysis was performed using the Student’s t-test. Data are
represented as means ± SD. *P\0.05, **P\0.01
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M. tuberculosis
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C
Fig. 3 CD28SA treatment during M. tuberculosis infection increases
the percentage of CD25
?Foxp3
? T-cells but has no major effect on
bacterial burden. a BALB/c mice were treated i.p. with CD28
superagonist (CD28SA, D665, 50 lg/mouse) or isotype control
(MOCP31) either  week prior (CD28SA once) or  week prior
and 1 week (CD28SA twice) post aerosol with 100 CFU/lung of
M.tuberculosis.Micewerebledat1weekandkilledat2and10 weeks
post-infection.bExpressionofCD25
?andFoxp3
?onCD4
?-gatedcells
was measured by ﬂow cytometry in collagenase-treated lung and in
peripheral blood lymphocytes. The percentage of CD3
? lung cells
producing IL-10 and IFN-c are also represented. Lung cells were
harvestedfollowingcollagenasetreatmentandstimulatedwithPMAand
ionomycin in the presence of monensin for 4 h and subjected to
intracellularstaining.cThebacterialloadinlungs,spleen,andliverwere
determined at 2 and 10 weeks post M. tuberculosis infection. Data are
presented as log10 CFU per organ. Individual bacterial titers are given
togetherwithgroupmedians.Statisticalanalysiswasperformedusingan
unpaired two-tailed Student’s t-test. Data are represented as mean-
s ± SEM (n = 5m i c e / g r o u p ;* P\0.05, **P\0.01, ***P\0.001).
All data are obtained from one experiment
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123the host. In contrast, IL-4Ra-mediated alternative
macrophage activation has been proposed as a possible
mechanism to attenuate excessive inﬂammation. The
identiﬁcation of marker genes [37–42] as well as the gen-
eration of macrophage/neutrophil-speciﬁc IL-4Ra deﬁcient
mice (LysM cre IL-4Raa -/lox) and subsequent studies of
relevant experimental disease models have enabled us to
evaluate the role of IL-4Ra-mediated alternative macro-
phage activation in vivo. Together, these investigations
demonstrated the involvement of aaMphs in immuno-
modulation and suppression during infectious diseases, like
schistosomiasis [8], leishmaniasis [43], cryptococcosis
[44–46], as well as during non-infectious inﬂammatory
diseases, like proteoglycan-induced arthritis [46, 47], or
experimental autoimmune encephalomyelitis (EAE) [47].
Here, they seem to inﬂuence both innate and adaptive
immune responses, the latter by suppression of T-cell
proliferation [48, 49].
The role of IL-4Ra-responsiveness in helminthic
diseases
In helminth infection, like Nippostrongylus and Schisto-
soma, IL-13 turned out to be the essential factor for efﬁ-
cient expulsion and induction of goblet hyperplasia [8, 50],
as well as smooth cell hypercontraction [9]. Further studies
in experimental schistosomiasis uncovered, however, that
IL-4/IL-13-independent hyperplasia is possible [51], and
deﬁned the protective role of alternatively activated mac-
rophages by down-regulation of otherwise overshooting
T-cell responses [8]. In addition, the use of mice deﬁcient
for IL-4Ra on particular T-cell subsets revealed that both
CD4? Th cells and non-CD4? T-cells are involved in
avoiding early mortality and morbidity during schistoso-
miasis [10, 11].
Beneﬁcial and detrimental IL-4Ra-responsive cell types
in leishmaniasis
Infection studies in CD4? T-cell-speciﬁc IL-4Ra deﬁcient
BALB/c mice with Leishmania major, which causes cuta-
neous leishmaniasis, conﬁrmed the detrimental role of
IL-4-promoted Th 2 cells, but also suggested that IL-4Ra-
responsive cells are involved in protection against cutane-
ous leishmaniasis [52]. AaMph’s could be excluded as they
rather contribute to susceptibility in BALB/c mice by
inﬂuencing T-helper responses and facilitating evasion by
the parasite [43]. Currently, recently established dendritic
cell-speciﬁc IL-4Ra deﬁcient mice are employed to test the
possibility that DC instruction via IL-4 and/or IL-13 may
be the missing link.
Concluding remarks
CD28 and the IL-4Ra highlight the potency of costimula-
tory receptors and cytokines in ﬁne-tuning immune
responses to pathogens while avoiding host damage. While
‘‘knockout’’ and blocking experiments deﬁned important
roles for CD28 in T-cell memory and for IL-4R signaling
in the activation of an anti-inﬂammatory type of macro-
phages, the application of stimulatory CD28-speciﬁc mAb
makes use of two major host-protective pathways by
boosting Treg and Th2 activation, which in turn leads to
alternative activation of macrophages. Notably, in several
of the infectious disease models we have studied, it was
Table 1 Constitutive and
conditional IL-4Ra deﬁcient
mouse models
Mutant mouse strains Cell speciﬁcity Status
Constitutive mutation
IL-4Ra
-/- All cells Mohrs et al. [4]
IL-4Ra
lox/lox All cells (silent mutation) Herbert et al. [8]
Cell type deﬁciency
LysM
creIL-4Ra
-/lox Macrophages and neutrophils Herbert et al. [8]
SMMHC
creIL-4Ra
-/lox Smooth muscle cells Horsnell et al. [9]
Lck
creIL-4Ra
-/lox CD4
? T lymphocytes Leeto et al. [10]
iLck
creIL-4Ra
-/lox All T lymphocytes Dewals et al. [11]
CD4
creIL-4Ra
-/lox a/b
? TCR T lymphocytes Unpublished
MB1
creIL-4Ra
-/lox B lymphocytes Unpublished
CD11c
creIL-4Ra
-/lox Dendritic cells Unpublished
LysM
creLck
creIL-4Ra
-/lox Macrophages/neutrophils/CD4
? T cells Unpublished
Inducible & cell type deﬁciency
TetOIL4Ra
Tg All cells Unpublished
tTA-VAV
TgTetOIL4Ra
TgIL-4Ra
-/- Haematopoetic cells Unpublished
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123possible to use such mAb treatment to protect the host from
immunopathology without compromising pathogen con-
trol. This is of potential translational interest because we
found that high-dose corticosteroid treatment does not
interfere with the activation of Treg cells by CD28SA in
vivo [14], opening the possibility of controlling a potential
cytokine storm while maintaining the beneﬁcial activation
of this host-protective T-cell subset.
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